Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 clinical trial of the combination of CB-839 plus talazoparib in patients with renal cell carcinoma and triple negative and ER+ breast cancer

Trial Profile

A Phase 1/2 clinical trial of the combination of CB-839 plus talazoparib in patients with renal cell carcinoma and triple negative and ER+ breast cancer

Planning
Phase of Trial: Phase I/II

Latest Information Update: 12 Oct 2018

At a glance

  • Drugs Talazoparib (Primary) ; Telaglenastat (Primary)
  • Indications Breast cancer; Renal cell carcinoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 12 Oct 2018 New trial record
    • 05 Oct 2018 According to a Calithera Biosciences media release, the company is plannig to initiate this trial in first quarter of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top